Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Spinal Cord Injury | Drug: AXER-204 Drug: Placebo | Phase 1 Phase 2 |
AXER-204 is a human fusion protein that acts as a soluble decoy/trap for the myelin-associated inhibitors of axonal growth known as Nogo-A, MAG, and OMgp. AXER-204 and a surrogate protein used in early preclinical studies have been found to promote axon growth and recovery of function in animal models of spinal cord injury.
Part 1 of the trial is a multicenter, open-label, single ascending dose study in participants with chronic cervical spinal cord injury. Four cohorts of 6 participants each are planned, with participants within each cohort expected to receive the same dose of AXER-204.
Part 2 is a multicenter, randomized, double-blind, placebo-controlled, repeat dose study in chronic cervical spinal cord injury participants. Approximately 32 participants will be randomized (ratio 1:1) to receive repeated doses of AXER-204 or placebo (a phosphate buffered saline formulation). The dose level and dose frequency will be dependent upon outcomes from Part 1.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 56 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Part 1 is open-label single-ascending dose. Part 2 is double-blind, placebo-controlled, repeat dose. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Part 1 - None; Part 2 - Quadruple |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AXER-204 in Subjects With Chronic Spinal Cord Injury |
Actual Study Start Date : | July 16, 2019 |
Estimated Primary Completion Date : | June 2022 |
Estimated Study Completion Date : | June 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: AXER-204
Part 1 - Single ascending doses; Part 2 - Repeated dose
|
Drug: AXER-204
human NoGo Trap fusion protein
Other Names:
|
Placebo Comparator: Placebo
Part 2 only - Repeated dose
|
Drug: Placebo
Phosphate buffered saline formulation
|
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Confirmation by MRI of the following:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Contact: Gilbert Block, Chief Medical Officer, MD, PhD | 1-203-208-8925 | info@renetx.com |
United States, California | |
Keck Medicine of USC | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: Sandra Oviedo sandra.oviedo@med.usc.edu | |
Principal Investigator: Charles Liu, MD, PhD | |
United States, Georgia | |
Shepherd Center | Recruiting |
Atlanta, Georgia, United States, 30309 | |
Contact: Casey Kandilakis, PT,DPT,NCS casey.kandilakis@shepherd.org | |
Principal Investigator: Donald Leslie, MD | |
United States, Illinois | |
Shirley Ryan AbilityLab / Northwestern | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Cristal G. Gomez 312-926-9912 cristal.gomez@northwestern.edu | |
Principal Investigator: David Chen, MD | |
United States, Massachusetts | |
Spaulding Rehabilitation | Recruiting |
Boston, Massachusetts, United States, 02129 | |
Contact: Jenny Min 617-952-6173 jmin5@partners.org | |
Principal Investigator: Ross Zafonte, DO | |
Sub-Investigator: Chloe Slocum, MD, MPH | |
United States, Ohio | |
The Ohio State University Wexner Medical Center | Recruiting |
Columbus, Ohio, United States, 43210 | |
Contact: Amy Bartlett, BA, CCRC 614-366-9050 amy.bartlett@osumc.edu | |
Principal Investigator: Jan Schwab, MD, PhD | |
United States, Pennsylvania | |
Thomas Jefferson University | Recruiting |
Philadelphia, Pennsylvania, United States, 19107 | |
Contact: Marilyn Owens, RN, BSN 215-955-6579 marilyn.owens@jefferson.edu | |
Principal Investigator: Ralph Marino, MD |
Study Director: | George Maynard, PhD | ReNetX Bio |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | June 11, 2019 | ||||
First Posted Date ICMJE | June 18, 2019 | ||||
Last Update Posted Date | May 25, 2021 | ||||
Actual Study Start Date ICMJE | July 16, 2019 | ||||
Estimated Primary Completion Date | June 2022 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE |
|
||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures |
Change in International Standards to document remaining Autonomic Function after Spinal Cord Injury (ISAFSCI) scores [ Time Frame: Screening to Day 169 or 28 days after last dose and 6 months after last dose ] The ISAFSCI consists of patient reported responses on remaining autonomic function regarding regulation of heart rate, blood pressure, sweating, body temperature, breathing, urinary function, bowel function, and sexual function. Scores are assigned as 2=normal, 1=reduced or altered, 0=complete loss of control, or NT=unable to assess for each item.
|
||||
Descriptive Information | |||||
Brief Title ICMJE | AXER-204 in Participants With Chronic Spinal Cord Injury | ||||
Official Title ICMJE | A Multicenter, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AXER-204 in Subjects With Chronic Spinal Cord Injury | ||||
Brief Summary | This two-part trial will assess the safety, tolerability, pharmacokinetics, and efficacy of AXER-204 administered by lumbar puncture and slow bolus infusion. Part 1 will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of AXER-204. Part 2 will evaluate the safety, tolerability, pharmacokinetics, and efficacy of repeated doses AXER-204 in comparison to placebo. | ||||
Detailed Description |
AXER-204 is a human fusion protein that acts as a soluble decoy/trap for the myelin-associated inhibitors of axonal growth known as Nogo-A, MAG, and OMgp. AXER-204 and a surrogate protein used in early preclinical studies have been found to promote axon growth and recovery of function in animal models of spinal cord injury. Part 1 of the trial is a multicenter, open-label, single ascending dose study in participants with chronic cervical spinal cord injury. Four cohorts of 6 participants each are planned, with participants within each cohort expected to receive the same dose of AXER-204. Part 2 is a multicenter, randomized, double-blind, placebo-controlled, repeat dose study in chronic cervical spinal cord injury participants. Approximately 32 participants will be randomized (ratio 1:1) to receive repeated doses of AXER-204 or placebo (a phosphate buffered saline formulation). The dose level and dose frequency will be dependent upon outcomes from Part 1. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 Phase 2 |
||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Part 1 is open-label single-ascending dose. Part 2 is double-blind, placebo-controlled, repeat dose. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Part 1 - None; Part 2 - Quadruple Primary Purpose: Treatment
|
||||
Condition ICMJE | Chronic Spinal Cord Injury | ||||
Intervention ICMJE |
|
||||
Study Arms ICMJE |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
56 | ||||
Original Estimated Enrollment ICMJE |
66 | ||||
Estimated Study Completion Date ICMJE | June 2022 | ||||
Estimated Primary Completion Date | June 2022 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03989440 | ||||
Other Study ID Numbers ICMJE | RNX-AX204-101 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | ReNetX Bio, Inc. | ||||
Study Sponsor ICMJE | ReNetX Bio, Inc. | ||||
Collaborators ICMJE | Not Provided | ||||
Investigators ICMJE |
|
||||
PRS Account | ReNetX Bio, Inc. | ||||
Verification Date | May 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |